Mark Bodmer, Ph.D. has served as Chief Scientific Officer and President of Research and Development since 2016. Prior to joining Evelo, Mark was Vice President of New Medicines Therapeutics at UCB S.A. Mark also served as Senior Vice President of Immunoinflammation at GSK, as well as a member of the Board of Directors of BioIndustry Association. Mark received his Ph.D. from Cambridge University.
Julie Carretero has served as Chief People Officer since 2020. Prior to joining Evelo, Julie was Chief Human Resources Officer at FXI Corporation, a privately held manufacturing company. Prior to FXI, Julie served in roles of increasing responsibility at Novartis Pharmaceuticals, most recently as Human Resources Lead for the Cardiovascular Business Unit. Julie earned a B.S. from William Smith College.
Daniel Char, J.D., has served as General Counsel since 2018. Prior to joining Evelo, Daniel was Associate General Counsel at Smith & Nephew. Prior to Smith & Nephew, Daniel was General Counsel and Secretary of Targanta Therapeutics. Daniel has also served as Senior Associate General Counsel at Idenix Pharmaceuticals and Associate General Counsel at Biogen. Daniel earned a J.D. from Harvard Law School and a B.A. in Economics from Tufts University.
Andrea Itano, Ph.D., has served as Senior Vice President, Head of Research since 2017. Andrea has also served on the board of Global Arts Live, a Boston-based performing arts nonprofit organization, since 2019. Prior to joining Evelo, Andrea held multiple leadership roles at GlaxoSmithKline, including Vice President and Head of Tempero Discovery Unit. Andrea has experience as a lead researcher at Amgen, Roche, and as Chief Scientific Officer of Tempero Pharmaceuticals. Andrea received her Ph.D. from the University of California, Berkeley, and completed a Cancer Research Institute Irvington Postdoctoral Fellowship at the University of Minnesota.
Duncan McHale, M.B.B.S., Ph.D., has served as Chief Medical Officer since 2018. Prior to joining Evelo, Duncan was Director and Chief Executive Officer at Weatherden, Ltd., a clinical development consultancy firm. From 2011-2017, Duncan was the Head of Global Exploratory Development at UCB S.A, and prior to that as Head of Translational Sciences at AstraZeneca. Duncan received his M.B.B.S. from Newcastle University and his Ph.D. from the University of Leeds.
Mark Plinio, J.D., has served as Chief Commercial Office since June 2021. Prior to joining Evelo, Mark was Chief Commercial Officer and Senior Vice President, Marketing and Sales, at Ironwood Pharmaceuticals. Prior to joining Ironwood, he spent nearly two decades at Novartis Pharmaceuticals in roles of increasing responsibility in Legal, Marketing, and Sales, including serving as Head of Dermatology and Rheumatology Marketing, Cosentyx®. Prior to Novartis, Mark worked as an associate attorney at Skadden, Arps, Slate, Meagher & Flom, LLP and at Mudge, Rose, Guthrie, Alexander & Ferdon, LLP. He holds his J.D. from Seton Hall University School of Law and his B.A. in Economics and Legal Studies from Bucknell University.